CD274 and neoplasm: Additionally, during the enrollment period, pembrolizumab monotherapy was the preferred option for the 1L treatment of patients with a PD-L1-staining tumor proportion score ≥50% and was available in many countries in combination with pemetrexed and cisplatin or carboplatin, regardless of PD-L1 expression.